Cube Dx hybcell technology

COMPANION
DIAGNOSTICS

EGFR PATHWAY
COST EFFICIENT – SNP SPECIFIC - SENSITIVE

Early and mutant-specific results with constant costs even for a single sample.

more Info

EARLY
PATHOGEN ID

INTEGRATED SEPSIS DIAGNOSTICS
EARLY – SPECIFIC – MINIMUM SAMPLE

Highly sensitive identification of pathogens from whole blood in only 4 hours.

more Info

PATIENT
MONITORING

INTEGRATED SEPSIS DIAGNOSTICS
SUPPORTIVE – FAST – MINIMUM SAMPLE

Support of several clinical decisions based on a range of markers from only 100µL plasma in around 20min.

more Info

INTEGRATED SEPSIS DIAGNOSTICS

Sepsis is one of the most common causes of death, with someone dying every three seconds. It is more common than death from stroke or heart attacks in the general population. The number of sepsis hospitalisations doubled in the US between 2000 and 2008. Sepsis represents a huge burden on healthcare providers, with about 1 in 10 patients in intensive care units suffering from sepsis. The cost of sepsis hospitalisations in the US was $14.6 billion in 2008.

Cube Dx' Integrated Sepsis Diagnostics aids early initial sepsis diagnosis/confirmation, selection of optimal anti-infective therapy and assists monitoring of patient responses to the therapy. Biomarker-based patient monitoring supports several clinical decisions during therapy of sepsis (and other severe infections).
Meet us

Meet us next...

...at the European Students Conference (www.esc-berlin.com) in Berlin. Cube Dx presents its Integrated Sepsis Diagnostics during a focussed industry exhibition and seminar on 29th of September, 2016. Make sure to be there. If you want to meet, make an appointment using info@cubedx.com!

News Ticker

Latest News...

We believe that the simultaneous (and parallel) measurement and evaluation of a set of biomarkers could improve the quality of clinical decisions of sepsis treatment. At ANESTHESIOLOGY® 2015, organised by the American Society of Anesthesiologists, a first study dealing with the quality of prognosis for single inflammatory and kidney markers in comparison to a combination of two of these markers was presented. The study was carried out by the Clinics of the Ludwig-Maximilians-University, Munich in collaboration with Clinic Neuperlach of the Municipal Hospital Munich.

The authors conclude that a combination of an inflammatory and a kidney biomarker leads to a significantly better prognosis than the use of single biomarkers, and can therefore more readily identify patients that are most critically affected by the disease. The authors recommend the simultaneous measurement of biomarkers to stratify a patient’s risk to die or of suffering critical kidney failure.